NanoString and OnRamp BioInformatics Partner to Develop Cloud-Based Analysis Solutions for nCounter Data

Expanded Functionality to Support COVID-19 Research Immediately Available Through Early Access 


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis tools, this week announced a collaboration for the development of new analysis tools for data generated on NanoString’s nCounter® Analysis System. The new analysis functionality is built into ROSALIND™ , OnRamp’s cloud-based analysis suite that facilitates data visualization, exploration and collaboration. The companies are releasing these new capabilities through Early Access and immediately offering it to COVID-19 researchers performing critical host response studies on the nCounter platform. 

“ROSALIND offers powerful data analysis capabilities and a unique ability to facilitate collaboration amongst researchers,” said Joe Beechem, Chief Scientific Offer and SVP of R&D for NanoString. "This partnership represents a shared vision of accelerating research through making gene expression analysis simple and broadly accessible.” 

ROSALIND is a cloud platform that connects researchers to perform differential expression and pathway exploration in a real-time collaborative environment. The companies are working to make the popular features of NanoString’s nSolver analysis suite available within ROSALIND and are evaluating opportunities for joint development of new analysis solutions. OnRamp Bio recently launched the Coronavirus Community, where participating Scientists are provided with free Scientist access to ROSALIND and the ability to rapidly process datasets and share results with fellow collaborators within the Community. 

The nCounter Platform has been used in over 300 published studies of infectious disease on host immune response, including more than 4 COVID-19 publications. It’s high-plex and wide dynamic range enable studies of pathogen and host gene expression profiles simultaneously with a wide range of sample types. The company announced the availability of a beta panel spike in for COVID-19 research in April and has over 50 customers utilizing the reagents in their research. 

“We are excited to partner with NanoString on advanced tools for gene expression analysis and see opportunities to expand the cloud-based offerings for nCounter data analysis in the future.” said Tim Wesselman, CEO of OnRamp Bio. “Due to the urgent need for COVID-19 researchers to collaborate across geographies, we are making these new analysis and collaboration capabilities available immediately through Early Access.”